PRE-I-SPY Phase I/Ib Oncology Platform Program

Solid Tumor Clinical Trial

— PRE-I-SPY-PI  

Official title:

PRE-Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis: A Phase I/Ib Platform Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05868226
• Other study ID #: I-SPY-P1
• Status: Recruiting
• Phase: Phase 1
• Start date: December 22, 2022
• Est. completion date: December 30, 2027

Study information

• Verified date: November 2023
• Source: QuantumLeap Healthcare Collaborative
• Contact: Smita M Asare
• Phone: (855) 866-0505
• Email: smita.asare[@]quantumleaphealth.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

I-SPY Phase I/Ib (I-SPY-P1) is an open-label, multisite platform study designed to evaluate single agents or combinations in a metastatic treatment setting that may be relevant for breast cancer patients with the overall goal of moving promising drug regimens into the I-SPY 2 SMART Design Trial (NCT01042379) and/or other oncology-based trials in a timely manner.

Description:

The PRE-I-SPY/I-SPY-P1 study is a platform trial with multiple ongoing drug regimen arms. In most cases, the treatment arm will have a dose-finding group (Part 1) and a dose-expansion group (Part 2). Eligibility criteria will vary according to the experimental regimen. Participant eligibility may vary according to the arm or the part within the study arm, including with respect to diagnosis. Arms could include participants diagnosed with certain solid tumors or specifically with breast cancer. Arms may restrict enrollment to a certain molecular pathway abnormality or histologic diagnosis. The trial allows for various study arm designs, with the goal to complete analysis of a study arm in 12 to 18 months.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 54
• Est. completion date: December 30, 2027
• Est. primary completion date: December 30, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

General Inclusion Criteria (GIC):

• GIC1: The participant must have ability to understand and willingness to provide signed written informed consent prior to any study related assessments and procedures and for collection of archival FFPE blocks (freshly cut 14 unstained tumor slides would be acceptable).
• GIC2: Age = 18 years at the time of signing the informed consent
• GIC3: Gender: Male or female (premenopausal and postmenopausal)
• GIC4: ECOG performance status Grade 0-2
• GIC5: Estimated life expectancy > 12 weeks at the start of investigational medicinal product (IMP) treatment.
• GIC6: Adequate organ function, evidenced by the following laboratory results within 30

days of the start of IMP:

• Absolute neutrophil count = 1,500/mm3
• Platelet count = 100,000/mm3
• Hemoglobin = 9.0 g/dL with no blood transfusion in the past 28 days
• Total bilirubin = 1.5 x the upper limit of normal (ULN)
• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 3.0 x ULN
• Estimated Creatinine clearance (using Cockcroft-Gault formula) = 60 mL/min for small molecules and >30 mL/min for monoclonal antibodies unless otherwise specified in the Arm Specific Eligibility. These cut-off values may be modified with supporting data for specific drug regimens.
• GIC7: Non-Pregnant: Serum or urine pregnancy test must be negative within 14 days of IMP treatment start in women of childbearing potential. Pregnancy testing does not need to be pursued in patients who are judged as postmenopausal before enrollment, or who have undergone bilateral oophorectomy, total hysterectomy, or bilateral tubal ligation. If male, they must agree to refrain from donating sperm during treatment.
• GIC8: Contraception: Women of childbearing potential and men must be willing to use adequate contraception for the duration of protocol treatment. Additional information regarding contraception for the specific treatment arm will be added to the drug arm description. Adequate contraception is defined as one highly effective form (i.e., abstinence, (fe)male sterilization) OR two effective forms (e.g., non-hormonal IUD and condom / occlusive cap with spermicidal foam / gel / film / cream / suppository).
• GIC9: Prior therapy effects: Resolution of all acute toxic effects of prior therapy, including radiotherapy, to grade =1 and neuropathy to grade =2 (except toxicities not considered a safety risk for the patient) and recovery from surgical procedures.
• GIC10: Participant compliance: Patients who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
• Additional arm specific inclusion criteria as needed by drug arm regimen

General Exclusion Criteria (GEC):

• GEC1: Wash out periods: No other anticancer therapy within the following periods:
• chemotherapy or investigational agents, 3 weeks
• mitomycin C and nitrosoureas, 6 weeks
• radiotherapy, 3 weeks
• targeted therapy, 2 weeks
• MAbs, ADCs, and immunotherapy, 3 weeks
• endocrine therapy, no washout needed
• GEC2: Concurrent therapy with other Investigational Products.
• GEC3: Prior history of drug/regimen hypersensitivity: History of infusion-related reactions and/or hypersensitivity to IMP or excipients of the study drug/drugs which led to permanent discontinuation of the treatment.
• GEC4: Uncontrolled intercurrent illness including (active infection, diabetes, pulmonary embolism in the past 6 months, or psychiatric illness/social situations that would limit compliance with study requirements).
• GEC5: Cardiovascular disease: History (within 6 months prior to start IMP) of clinically significant cardiovascular disease such as unstable angina, congestive heart failure (CHF), myocardial infarction, uncontrolled hypertension, cardiac arrhythmia requiring medication, or baseline corrected QT by Fridericia's formula (QTcF) length > 470 msec for men and women. The QTcF cut-off value may be modified with supporting data for specific drug regimens.
• GEC6: CNS tumoral spread: Active uncontrolled/symptomatic central nervous system cancer/spinal cord compression. Previously treated and clinically stable lesions, as per Investigator's judgment, are permitted.
• GEC7: Liver disease: Patients with clinically significant history of liver disease, including viral or other known hepatitis, current alcohol abuse, or cirrhosis.
• GEC8: Recent major surgery within 4 weeks prior to start IMP treatment
• GEC9: Pregnancy or breastfeeding
• GEC10: Individuals accommodated in an institution because of regulatory or legal order; prisoners or participants who are legally institutionalized.
• GEC11: Other conditions, which in the opinion of the investigator, would compromise the safety of the patient or the patient's ability to complete the study.
• Additional arm specific exclusion criteria as needed by drug arm regimen

Related Conditions & MeSH terms

• Breast Neoplasms
• Carcinoma
• ER Positive Breast Cancer
• Estrogen Receptor Positive Tumor
• HER-2 Protein Overexpression
• HER2-negative Breast Cancer
• HER2-positive Breast Cancer
• HER2-positive Metastatic Breast Cancer
• Hormone Receptor-positive Breast Cancer
• Metastatic
• Metastatic Breast Cancer
• Metastatic Cancer
• PR-positive Breast Cancer
• Progesterone Receptor-positive Breast Cancer
• Solid Carcinoma
• Solid Tumor
• Solid Tumor, Adult
• Triple Negative Breast Cancer
• Triple Negative Breast Neoplasms

Intervention

Drug:
• ALX148
CD47 Inhibitor: A fusion protein containing a high affinity engineered D1 domain of human signal regulatory protein alpha (SIRPa) variant 1 (v1) genetically linked to a modified and inactive Fc domain of human immunoglobulin (Ig) G1.
• Fam-Trastuzumab Deruxtecan-Nxki
Antibody-drug conjugate (ADC): A recombinant humanized anti-human HER2 IgG1 monoclonal antibody, conjugated with linker to a Topoisomerase I inhibitor
• Zanidatamab
Bispecific HER2 antibody: A humanized, bispecific, immunoglobulin G isotype 1 (IgG1)-like antibody directed against the juxtamembrane extracellular domain (ECD4) and the dimerization domain (ECD2) of human epidermal growth factor receptor 2 (HER2).
• Tucatinib
Small molecule tyrosine kinase inhibitor (TKI) of HER2 (oral drug).

Locations

Country	Name	City	State
United States	The University of Chicago Medicine Comprehensive Cancer Center	Chicago	Illinois
United States	The University of Texas MD Anderson Cancer Center	Houston	Texas
United States	University of Minnesota Masonic Cancer Center	Minneapolis	Minnesota
United States	UChicago Medicine Comprehensive Cancer Center at Silver Cross Hospital	New Lenox	Illinois
United States	UChicago Medicine Orland Park	Orland Park	Illinois

Sponsors (1)

Lead Sponsor	Collaborator
QuantumLeap Healthcare Collaborative

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of Adverse Events related to the treatment	Evaluate the number of adverse events related to the treatment according to the current version of CTCAE during the trial.	Start of treatment to 30 days post treatment (estimated 12 -18 months)
Primary	Incidence of Dose Limiting Toxicities (DLTs) at each dose level	To determine the safety and tolerability of new agents/regimens in participants with certain advanced solid tumors and breast cancer. DLT rate (number of participants who experience a protocol defined DLT/total number of DLT cohort participants at that dose).	DLT observation period: Start of treatment to 21 days (Cycle 1)
Primary	Maximum Tolerated Dose (MTD)	The maximum dose level (mg/kg) which is not eliminated.	Start of treatment to the date of last participant at end of DLT observation period at highest dose level (estimated 6 months)
Primary	Recommended Phase 2 Dose (RP2D)	Using all available data, computation of RP2D (mg/kg), which may not be the MTD.	Start of treatment to the date of last participant at highest dose level (estimated 6 months)
Primary	Overall Response Rate (ORR)	To obtain preliminary efficacy data of the new agents/regimens in participants with certain advanced solid tumors and breast cancer.	Start of treatment to 12 months
Primary	Duration of Response (DOR)	To obtain preliminary efficacy data of the new agents/regimens in participants with certain advanced solid tumors and breast cancer.	Start of treatment to 12 months
Secondary	Progression Free Survival (PFS) - descriptive	To provide descriptive assessment of Progression Free Survival (PFS) of the new agents/regimens with certain advanced solid tumors and breast cancer	Start of treatment to 12 months
Secondary	Clinical Benefit Rate (CBR) at 6 months	To obtain preliminary Clinical Benefit Rate (CBR) at 6 months of participants treated with the new agents/regimens.	Start of treatment to 6 months